효소 억제제 시장 규모는 향후 수년간 안정된 성장이 예상됩니다. 2029년에는 CAGR 4.6%로 2,266억 5,000만 달러로 성장합니다. 예측기간의 성장은 연구개발 활동에 대한 투자 확대, 맞춤형 의료에 대한 수요 증가, 신흥국 시장에서의 만성 질환 이환율의 상승, 암 치료에 있어서의 효소 억제제 수요 증가, 희귀질환이나 유전성 질환에의 응용 확대 등에 기인하는 것으로 예상됩니다. 예측 기간의 주요 동향으로는 가역성 및 비가역성 효소 억제제의 개발, 효소 억제제공급원으로서의 천연물의 탐색, 효소 억제제 탐색에 있어서의 계산 방법의 통합, 개별화 투여 및 치료 요법의 중시, 종양학 및 신경 변성 질환에 있어서의 효소 억제제 응용의 확대 등을 들 수 있습니다.
암을 포함한 질병 발생률 증가는 효소 억제제 시장의 향후 성장을 가속할 것으로 예상됩니다. 대부분의 종양세포에서 활성을 가지는 텔로머라제 등의 효소는 백혈병을 포함한 암을 치료하는데 이용되며, 또한 건강한 성인세포가 암화되는 것을 막습니다. 예를 들어, 암 박멸을 목표로 하는 미국의 비영리 헬스케어 단체인 미국 암 협회에 따르면, 2022년 1월, 미국에서는 매일 평균 1,670명이 암으로 사망하고, 190만명이 암으로 진단되고, 60만 9,360명이 사망한다고 합니다. 따라서 암 등 질병 발생률 증가가 효소 억제제 시장의 성장 수요를 견인하고 있습니다.
개인화된 의료에 대한 수요 증가는 앞으로 수년간 효소 억제제 시장의 성장을 가속할 것으로 예상됩니다. 맞춤형 의료는 정밀의료라고도 불리며, DNA, 주위 환경, 라이프 스타일에서 각 사람 고유의 다양성을 고려한 의료 및 치료 방법입니다. 효소 억제제는 특정 개인과 질병의 하위유형에 맞게 조정할 수 있기 때문에 맞춤형 의료의 귀중한 도구이며, 집중치료, 정밀의료, 진단, 창약 등 맞춤형 의료에 있어서 폭넓은 용도가 있습니다. 예를 들어, 미국에 기반한 제약, 생명공학, 진단, IT기업, 의료 제공업체, 지불자의 비영리단체인 맞춤형 의료연합(Personalized Medicine Coalition)에 따르면, 2022년에는 개별화의료는 미국 식품의약국(FDA)에 의한 신약 승인의 34%에 기여해 지난 8년간은 모두 승인 따라서 맞춤형 의료에 대한 수요가 증가함에 따라 효소 억제제 시장을 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시 경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 효소 억제제 시장의 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
- 최종 이용 산업의 분석
- 세계의 효소 억제제 시장의 성장률 분석
- 세계의 효소 억제제 시장 실적 : 규모와 성장, 2019-2024년
- 세계의 효소 억제제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
- 세계의 효소 억제제 총 주소 가능 시장(TAM)
제6장 시장 세분화
- 세계의 효소 억제제 시장 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 양성자 펌프 억제제(PPI)
- 프로테아제 억제제
- 역전사효소 억제제
- 아로마타제 억제제
- 키나제 억제제
- 뉴라미니다제 억제제
- 스타틴
- 기타 유형
- 세계의 효소 억제제 시장 : 적응증별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 만성 폐색성 폐질환
- 심혈관 질환
- 위장 장애
- 관절염
- 염증성 질환
- 기타 질환
- 세계의 효소 억제제 시장 : 용도별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 화학요법
- 항생제
- 농약
- 심장혈관 치료
- 기타 용도
- 세계의 효소 억제제 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 제약
- 생명공학
- 식품 및 음료
- 기타 최종 사용자
- 세계의 효소 억제제 시장 : 양성자 펌프 억제제(PPI)의 서브 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 오메프라졸
- 에소메프라졸
- 란소프라졸
- 판토프라졸
- 라베프라졸
- 세계의 효소 억제제 시장 : 프로테아제 억제제의 서브 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 리토나 빌딩
- 로피나 빌딩
- 아타자나 빌딩
- 사키나 빌딩
- 다르나빌
- 세계의 효소 억제제 시장 :역전사효소 억제제의 서브 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- NRTI(뉴클레오시드 역전사효소 억제제)
- NNRTI(비뉴클레오시드계 역전사효소 억제제)
- 세계의 효소 억제제 시장 : 아로마타제 억제제의 서브 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 아나스트로졸
- 레트로졸
- 엑세메스탄
- 세계의 효소 억제제 시장 : 키나제 억제제의 서브 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- BCR-ABL 억제제
- EGFR 억제제
- ALK 억제제
- MEK 억제제
- 세계의 효소 억제제 시장 : 노이라미니다제 억제제의 서브 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 오셀타미비르
- 자나미빌
- 페라미빌
- 세계의 효소 억제제 시장 :스타틴의 서브 세분화:유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 아토르바스타틴
- 심바스타틴
- 로스바스타틴
- 로바스타틴
- 세계의 효소 억제제 시장 : 기타 유형의 서브 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 항엽산제
- 포스포디에스테라아제 억제제
- 시클로옥시게나제 억제제
제7장 지역별·국가별 분석
- 세계의 효소 억제제 시장 :지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
- 세계의 효소 억제제 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 효소 억제제 시장 : 경쟁 구도
- 효소 억제제 시장 : 기업 프로파일
- Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
- Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업 및 혁신 기업
- Pfizer Inc.
- Takeda Pharmaceutical Company
- Merck and Co. Inc.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Cipla USA Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Janssen Pharmaceuticals
- Acellera Ltd.
- Bioinfogate SL
- BioSolveIT GmbH
- Dassault Systemes BIOVIA Corp.
- ChemAxon Ltd.
- Cheminformatics Tools and Services LLC
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 시장의 최근 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 효소 억제제 시장 2029년 - 가장 새로운 기회를 제공하는 국가
- 효소 억제제 시장 2029년 - 가장 새로운 기회를 제공하는 부문
- 효소 억제제 시장 2029년 - 성장 전략
제36장 부록
SHW
Enzyme inhibitor refers to a chemical that inhibits an enzyme's activity. Enzymes participate in a variety of cell processes, including cell signaling, growth, and division, as well as accelerating chemical reactions in the body. Enzymes help to speed up chemical reactions in the body and take part in many cell functions, including cell signaling, growth, and division.
The main types of enzyme inhibitors are proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, aromatase inhibitors, kinase inhibitors, neuraminidase inhibitors, statins, and other types. Proton pump inhibitors refer to medicines that work by decreasing the amount of stomach acid made by glands in the lining of the stomach. The various disease indications include chronic obstructive pulmonary disorders, cardiovascular disease, gastrointestinal disorders, arthritis, inflammatory diseases, and others. The enzyme inhibitors are applicable in chemotherapy, antibiotics, pesticides, cardiovascular treatments, and others and are used in pharmaceuticals, biotechnology, food and beverage, and other end users.
The enzyme inhibitors market research report is one of a series of new reports from The Business Research Company that provides enzyme inhibitors market statistics, including enzyme inhibitors industry global market size, regional shares, competitors with an enzyme inhibitors market share, detailed enzyme inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the enzyme inhibitors industry. This enzyme inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The enzyme inhibitor market size has grown steadily in recent years. It will grow from $183.8 billion in 2024 to $189.26 billion in 2025 at a compound annual growth rate (CAGR) of 3.0%. The growth in the historic period can be attributed to increased demand for enzyme inhibitors inThe treatment of various diseases, advancements in drug discovery and development, growing prevalence of chronic diseases, increased geriatric population, rising awareness aboutThe benefits of enzyme inhibitors.
The enzyme inhibitor market size is expected to see steady growth in the next few years. It will grow to $226.65 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to growing investment in research and development activities, increasing demand for personalized medicine, rising incidence of chronic diseases in emerging markets, growing demand for enzyme inhibitors in the treatment of cancer, expansion of applications in rare and genetic diseases. Major trends in the forecast period include development of reversible and irreversible enzyme inhibitors, exploration of natural products as sources of enzyme inhibitors, integration of computational methods in enzyme inhibitor discovery, emphasis on personalized dosing and treatment regimens, expansion of enzyme inhibitor applications in oncology and neurodegenerative diseases.
The rise in the incidence of diseases including cancer is expected to propel the growth of the enzyme inhibitor market going forward. Enzymes, such as telomerase, which is active in most tumor cells, are utilized to cure cancers, including leukemia, and also keep healthy adult cells from becoming cancerous. For instance, in January 2022, according to the American Cancer Society, a US-based non-profit healthcare group dedicated to cancer elimination, on average in the US, 1,670 individuals are going to die from cancer every day in 2022, with 1. 9 million cases being diagnosed and 609,360 fatalities. Therefore, the rise in the incidence of diseases such as cancer is driving the demand for the enzyme inhibitor market growth.
The increasing demand for personalized medicine is expected to propel the growth of the enzyme inhibitor market in the coming years. Personalized medicine, additionally referred to as precision medicine, is a health care and treatment method that considers each person's specific diversity in DNA, surroundings, and lifestyle. Enzyme inhibitors are a valuable tool in personalized medicine because they can be adjusted to particular individuals or disease subtypes and have a wide range of applications in personalized medicine, including focused therapy, precision medicine, diagnostics, and drug discovery. For instance, in 2022, according to the Personalized Medicine Coalition, a US-based nonprofit umbrella association for pharmaceuticals, biotechnology, diagnosis, and information technology firms, as well as healthcare providers and payers, personalized medications contributed to 34% of new drug approvals by the US Food and Drug Administration and had been responsible for at least 25% of approvals in each of the previous eight years. Therefore, the increasing demand for personalized medicine is driving the enzyme inhibitor market.
Leading companies in the enzyme inhibitor market are prioritizing innovative therapies, such as selective kinase inhibitors, to enhance treatment options and improve patient outcomes across various diseases. Jaypirca (pirtobrutinib) is a highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor approved by the FDA for treating adult patients with relapsed or refractory mantle cell lymphoma after at least two prior systemic treatments. For example, in January 2023, Loxo Oncology at Lilly, the oncology division of Eli Lilly and Company, a U.S.-based pharmaceutical firm, introduced Jaypirca tablets. It is the first and only non-covalent (reversible) BTK inhibitor approved by the Food and Drug Administration (FDA), a U.S.-based health organization. This approval marks a major breakthrough for patients with mantle cell lymphoma (MCL) who have exhausted current treatment options. Jaypirca offers a novel approach to targeting the BTK pathway, potentially improving outcomes for this patient group.
Major companies operating in the enzyme inhibitor market are focusing on developing innovative products, such as Sotyktu, to better meet the needs of their existing consumers. Sotyktu is an allosteric tyrosine kinase 2 (TYK2) inhibitor drug intended to inhibit or limit the activity of the TYK2 enzyme by attaching to a location on the enzyme other than its active site. For instance, in September 2022, Bristol-Myers Squibb Company, a US-based pharmaceutical firm, announced the approval of Sotyktu, a selective oral allosteric tyrosine kinase 2 (TYK2) inhibitor that is the first of its kind by the U. S. Food and Drug Administration. Sotyktu is a prescription medication authorized for treating people with moderate-to-severe plaque psoriasis who are not candidates for systemic therapy or phototherapy. 1,2 Sotyktu should not be used in conjunction with other strong immunosuppressants. Sotyktu can serve as the new standard of care for oral therapy for persons with moderate-to-severe plaque psoriasis due to its track record of assisting patients in attaining smoother skin in the POETYK PSO clinical study.
In August 2024, Eli Lilly and Company, a U.S.-based pharmaceutical firm, acquired Morphic Holding, Inc. for an undisclosed sum. Through this acquisition, Eli Lilly seeks to expand its therapeutic portfolio in gastroenterology, drive innovation in treatment options for inflammatory bowel disease, bolster its market presence, capitalize on research synergies, and increase patient access to effective therapies. Morphic Holding Inc. is a U.S.-based biopharmaceutical company focused on developing enzyme inhibitors.
Major companies operating in the enzyme inhibitor market include Abbott Laboratories, Amgen Inc., AstraZeneca plc, Bayer AG, F. Hoffmann-La Roche AG, Pfizer Inc., Takeda Pharmaceutical Company, Merck and Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Cipla USA Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Acellera Ltd., Bioinfogate SL, BioSolveIT GmbH, Dassault Systemes BIOVIA Corp., ChemAxon Ltd., Cheminformatics Tools and Services LLC, Cresset BioMolecular Discovery Ltd., Dotmatics Limited, Enamine Ltd., Forge Therapeutics Inc., Inte:Ligand GmbH, LeadIT, Molecular Forecaster Inc., Chemical Computing Group Inc., OpenEye Scientific Software Inc.
North America was the largest region in the enzyme inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enzyme inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the enzyme inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
The enzyme inhibitor market consists of sales of competitive, noncompetitive, and uncompetitive inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Enzyme Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on enzyme inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for enzyme inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The enzyme inhibitor market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Proton Pump Inhibitors (PPIs); Protease Inhibitors; Reverse Transcriptase Inhibitors; Aromatase Inhibitors; Kinase Inhibitors; Neuraminidase Inhibitors; Statins; Other Types
- 2) By Disease Indication: Chronic Obstructive Pulmonary Disorders; Cardiovascular Disease; Gastrointestinal Disorders; Arthritis; Inflammatory Diseases; Other Disease Indications
- 3) By Application: Chemotherapy; Antibiotics; Pesticides; Cardiovascular Treatments; Other Applications
- 4) By End User: Pharmaceutical; Biotechnology; Food And Beverage; Other End Users
- Subsegments:
- 1) By Proton Pump Inhibitors (PPIs): Omeprazole; Esomeprazole; Lansoprazole; Pantoprazole; Rabeprazole
- 2) By Protease Inhibitors: Ritonavir; Lopinavir; Atazanavir; Saquinavir; Darunavir
- 3) By Reverse Transcriptase Inhibitors: NRTIs (Nucleoside Reverse Transcriptase Inhibitors); NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors)
- 4) By Aromatase Inhibitors: Anastrozole; Letrozole; Exemestane
- 5) By Kinase Inhibitors: BCR-ABL Inhibitors; EGFR Inhibitors; ALK Inhibitors; MEK Inhibitors
- 6) By Neuraminidase Inhibitors: Oseltamivir; Zanamivir; Peramivir
- 7) By Statins: Atorvastatin; Simvastatin; Rosuvastatin; Lovastatin
- 8) By Other Types: Antifolates; Phosphodiesterase Inhibitors; Cyclooxygenase Inhibitors
- Companies Mentioned: Abbott Laboratories; Amgen Inc.; AstraZeneca plc; Bayer AG; F. Hoffmann-La Roche AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Enzyme Inhibitor Market Characteristics
3. Enzyme Inhibitor Market Trends And Strategies
4. Enzyme Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Enzyme Inhibitor Growth Analysis And Strategic Analysis Framework
- 5.1. Global Enzyme Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Enzyme Inhibitor Market Growth Rate Analysis
- 5.4. Global Enzyme Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Enzyme Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Enzyme Inhibitor Total Addressable Market (TAM)
6. Enzyme Inhibitor Market Segmentation
- 6.1. Global Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Proton Pump Inhibitors (PPIs)
- Protease Inhibitors
- Reverse Transcriptase Inhibitors
- Aromatase Inhibitors
- Kinase Inhibitors
- Neuraminidase Inhibitors
- Statins
- Other Types
- 6.2. Global Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chronic Obstructive Pulmonary Disorders
- Cardiovascular Disease
- Gastrointestinal Disorders
- Arthritis
- Inflammatory Diseases
- Other Disease Indications
- 6.3. Global Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy
- Antibiotics
- Pesticides
- Cardiovascular Treatments
- Other Applications
- 6.4. Global Enzyme Inhibitor Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pharmaceutical
- Biotechnology
- Food and Beverage
- Other End Users
- 6.5. Global Enzyme Inhibitor Market, Sub-Segmentation Of Proton Pump Inhibitors (PPIs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Omeprazole
- Esomeprazole
- Lansoprazole
- Pantoprazole
- Rabeprazole
- 6.6. Global Enzyme Inhibitor Market, Sub-Segmentation Of Protease Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Ritonavir
- Lopinavir
- Atazanavir
- Saquinavir
- Darunavir
- 6.7. Global Enzyme Inhibitor Market, Sub-Segmentation Of Reverse Transcriptase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- NRTIs (Nucleoside Reverse Transcriptase Inhibitors)
- NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors)
- 6.8. Global Enzyme Inhibitor Market, Sub-Segmentation Of Aromatase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anastrozole
- Letrozole
- Exemestane
- 6.9. Global Enzyme Inhibitor Market, Sub-Segmentation Of Kinase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- BCR-ABL Inhibitors
- EGFR Inhibitors
- ALK Inhibitors
- MEK Inhibitors
- 6.10. Global Enzyme Inhibitor Market, Sub-Segmentation Of Neuraminidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oseltamivir
- Zanamivir
- Peramivir
- 6.11. Global Enzyme Inhibitor Market, Sub-Segmentation Of Statins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Atorvastatin
- Simvastatin
- Rosuvastatin
- Lovastatin
- 6.12. Global Enzyme Inhibitor Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antifolates
- Phosphodiesterase Inhibitors
- Cyclooxygenase Inhibitors
7. Enzyme Inhibitor Market Regional And Country Analysis
- 7.1. Global Enzyme Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Enzyme Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Enzyme Inhibitor Market
- 8.1. Asia-Pacific Enzyme Inhibitor Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Enzyme Inhibitor Market
- 9.1. China Enzyme Inhibitor Market Overview
- 9.2. China Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Enzyme Inhibitor Market
- 10.1. India Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Enzyme Inhibitor Market
- 11.1. Japan Enzyme Inhibitor Market Overview
- 11.2. Japan Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Enzyme Inhibitor Market
- 12.1. Australia Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Enzyme Inhibitor Market
- 13.1. Indonesia Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Enzyme Inhibitor Market
- 14.1. South Korea Enzyme Inhibitor Market Overview
- 14.2. South Korea Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Enzyme Inhibitor Market
- 15.1. Western Europe Enzyme Inhibitor Market Overview
- 15.2. Western Europe Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Enzyme Inhibitor Market
- 16.1. UK Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Enzyme Inhibitor Market
- 17.1. Germany Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Enzyme Inhibitor Market
- 18.1. France Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Enzyme Inhibitor Market
- 19.1. Italy Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Enzyme Inhibitor Market
- 20.1. Spain Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Enzyme Inhibitor Market
- 21.1. Eastern Europe Enzyme Inhibitor Market Overview
- 21.2. Eastern Europe Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Enzyme Inhibitor Market
- 22.1. Russia Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Enzyme Inhibitor Market
- 23.1. North America Enzyme Inhibitor Market Overview
- 23.2. North America Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Enzyme Inhibitor Market
- 24.1. USA Enzyme Inhibitor Market Overview
- 24.2. USA Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Enzyme Inhibitor Market
- 25.1. Canada Enzyme Inhibitor Market Overview
- 25.2. Canada Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Enzyme Inhibitor Market
- 26.1. South America Enzyme Inhibitor Market Overview
- 26.2. South America Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Enzyme Inhibitor Market
- 27.1. Brazil Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Enzyme Inhibitor Market
- 28.1. Middle East Enzyme Inhibitor Market Overview
- 28.2. Middle East Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Enzyme Inhibitor Market
- 29.1. Africa Enzyme Inhibitor Market Overview
- 29.2. Africa Enzyme Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Enzyme Inhibitor Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Enzyme Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Enzyme Inhibitor Market Competitive Landscape And Company Profiles
- 30.1. Enzyme Inhibitor Market Competitive Landscape
- 30.2. Enzyme Inhibitor Market Company Profiles
- 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
31. Enzyme Inhibitor Market Other Major And Innovative Companies
- 31.1. Pfizer Inc.
- 31.2. Takeda Pharmaceutical Company
- 31.3. Merck and Co. Inc.
- 31.4. Eli Lilly and Company
- 31.5. Bristol-Myers Squibb Company
- 31.6. Cipla USA Inc.
- 31.7. AbbVie Inc.
- 31.8. Teva Pharmaceutical Industries Ltd.
- 31.9. Janssen Pharmaceuticals
- 31.10. Acellera Ltd.
- 31.11. Bioinfogate SL
- 31.12. BioSolveIT GmbH
- 31.13. Dassault Systemes BIOVIA Corp.
- 31.14. ChemAxon Ltd.
- 31.15. Cheminformatics Tools and Services LLC
32. Global Enzyme Inhibitor Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Enzyme Inhibitor Market
34. Recent Developments In The Enzyme Inhibitor Market
35. Enzyme Inhibitor Market High Potential Countries, Segments and Strategies
- 35.1 Enzyme Inhibitor Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Enzyme Inhibitor Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Enzyme Inhibitor Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
